Suppr超能文献

术前 CA19-9:肝切除术后结直肠癌肝转移患者复发的竞争预测因子。

Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy.

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Hepatopancreatobiliary Surgery Department I, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, China.

出版信息

Int J Colorectal Dis. 2021 Apr;36(4):767-778. doi: 10.1007/s00384-020-03828-z. Epub 2021 Jan 9.

Abstract

PURPOSE

The role of preoperative carbohydrate antigen 19-9 (CA19-9) in colorectal cancer liver metastases (CRLM) patients is still unclear. The present study aimed to explore the prognostic significance of preoperative CA19-9 in those patients.

METHODS

A total of 691 CRLM patients were included in this study. X-tile analyses were performed to determine the optimal cut-off values of CA19-9 and carcinoembryonic antigen (CEA). Prognostic predictors were identified by multivariate analyses.

RESULTS

The optimal cut-off values of CA19-9 and CEA for 5-year recurrence-free survival (RFS) were 35.24 U/ml and 20.4 ng/ml, respectively. Patients with high-level CA19-9 had significantly worse RFS and overall survival (OS) than those with low-level CA19-9 (P = 0.001 and P = 0.002, respectively). In addition, patients with high-level CA19-9 had poor RFS and OS (P = 0.028 and P = 0.011, respectively) at low-level CEA. Multivariate analyses confirmed that preoperative CA19-9 was an independent predictor for RFS (hazard ratio [HR] 1.295; 95% confidence interval [CI] 1.043-1.607; P = 0.019) but not for OS (HR 1.213; 95% CI 0.902-1.631; P = 0.201).

CONCLUSION

CA19-9 is a promising predictor of recurrence for CRLM patients undergoing hepatectomy, and an effective supplement for patients with low-level CEA.

摘要

目的

术前糖类抗原 19-9(CA19-9)在结直肠癌肝转移(CRLM)患者中的作用仍不清楚。本研究旨在探讨术前 CA19-9 对这些患者的预后意义。

方法

共纳入 691 例 CRLM 患者。采用 X-tile 分析确定 CA19-9 和癌胚抗原(CEA)的最佳截断值。通过多变量分析确定预后预测因子。

结果

CA19-9 和 CEA 预测 5 年无复发生存(RFS)的最佳截断值分别为 35.24 U/ml 和 20.4 ng/ml。高水平 CA19-9 的患者 RFS 和总生存期(OS)明显差于低水平 CA19-9 的患者(P=0.001 和 P=0.002)。此外,CA19-9 高水平患者在 CEA 低水平时 RFS 和 OS 较差(P=0.028 和 P=0.011)。多变量分析证实术前 CA19-9 是 RFS 的独立预测因素(危险比 [HR] 1.295;95%置信区间 [CI] 1.043-1.607;P=0.019),但不是 OS 的独立预测因素(HR 1.213;95% CI 0.902-1.631;P=0.201)。

结论

CA19-9 是预测结直肠癌肝切除术后复发的有前途的指标,是 CEA 水平低的患者的有效补充。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验